Fayetteville VA Medical Center, Fayetteville, NC

Is Fayetteville VA Medical Center registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Fayetteville VA Medical Center hold a North Carolina pharmacy license?

State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.

Has Fayetteville VA Medical Center had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Jun 15, 2026) for Fayetteville VA Medical Center. State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Fayetteville VA Medical Center
Location
Fayetteville, NC
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 15, 2026
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 3 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Fayetteville VA Medical Center, a 503A facility, with 1 dated action.

Document
Jun 15, 2026Form 483483 Issued 06/15/2026fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jun 8, 2026 to Jun 15, 2026: 3 observations

Firm on the cover
Fayetteville VA Medical Center, 2300 Ramsey St, Fayetteville, NC 28301-3856
FEI number
1073803
Establishment type on the cover
Producer of sterile drug products
FDA district office on the cover
109 Holton Street Winchester, MA 01890
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Microbial contamination was present in the.

Specifically,

On 05/08/2025, a surface sample collected from <Redacted B4> (S/N: <Redacted B4>), an ISO Class 5 used for the production of sterile drug products, yielded 4 cfu/plate, exceeding the action limit of <Redacted B4> cfu/plate. The sample was classified as Out of Compliance (OOC) and the following organisms were identified: Cladosporium spp. (pathogenic), Corynebacterium tuberculostearicum, Staphylococcus saprophyticus L and Fungal Overgrowth. Per email documentation provided by the firm, the <Redacted B4> (S/N; <Redacted B4>) was not used following the OOC result until passing recertification, which occurred approximately <Redacted B4> later. Your firm failed to investigate the cause of the OOC result and implement a corrective action plan as required by your Policy Number 797-2022, entitled, Microbiological Air and Surface Monitoring Program, version 2. Additionally, your firm was unable to demonstrate that the 6R4 was not used for the production of sterile drug products during this period.

Observation 2

Fairlue to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.

Specifically,

• Areas of reddish-brown and opaque discoloration/staining were observed on the ceiling screen cover within the ISO-5 <Redacted B4> S/N: <Redacted B4>

• On 06/08/2026, we observed a technician conduct cleaning and disinfection of the ISO-5 <Redacted B4> S/N: <Redacted B4>. We observed that the technician failed to clean the recessed area of a <Redacted B4> on the side of the <Redacted B4>. The technician was instructed to clean the <Redacted B4> and brown residue was observed on the wipe.

The aforementioned <Redacted B4> is utilized in the production of several sterile products including:

Piperacillin/Tazobactam 2.25gm/vial; Doxycycline Hyclate 100mg/vial; Ampicillin/Sulbactaml.5gin/vial; Vancomycin HCL l gin/vial and Infliximab I00mg/vial

Observation 3

Beta-lactam drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

Specifically,

• The firm has routinely reduced both Beta-lactam and non-Beta-lactam drug products within the same ISO 5 <Redacted B4>. S/N: <Redacted B4> and (S/N: <Redacted B4>). During this time the firm's procedure "Cleaning and Disinfecting Compounding Areas" only require the operator to apply sterile <Redacted B4> to surfaces <Redacted B4> production. For example, the firm produced Piperacillin Tazobactam 4.5g7vial Injection; Sodium Chloride 0.9% Injection Bag Bag 100ml on 05/28/2026. The firm failed to conduct decontamination of the <Redacted B4> then produced Phosphorus 3mmol/Potassium 4.4 Meq/ml Injection; Sodium Chloride 0.9% Injection Bag 250ml.

• On 06/09/2026, we observed production within 1SO-5 <Redacted B4>) S/N: <Redacted B4>. We then observed that the technician only applied <Redacted B4> to the <Redacted B4> of the <Redacted B4> and no on other surfaces. ...

Read the full 483 (PDF on fda.gov)

State board of pharmacy records

State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.